Late-Breaking Science - International Stroke Conference
Pre-Con Sessions: February 4, 2025
ISC Sessions: February 5–7, 2025
Los Angeles Convention Center | Los Angeles, California
ISC Sessions: February 5–7, 2025
Los Angeles Convention Center | Los Angeles, California
The most anticipated studies of the year!
#ISC25 has the most highly-anticipated clinical trial breakthroughs and discoveries of the year! Join us in Los Angeles, California for results for ESCAPE-MeVO; DISTAL; DISCOUNT; BEST; TRACE; PRESTIGE-AF; MIND; TRANSPORT2; ANGEL-TNK; ETERNAL-LVO; PEARL; ATIS-NVAF; LAMP and so much more!
PLEASE NOTE: All Late-Breaking Science Main Event and Concurrent Abstract Sessions are embargoed to the date and time of presentation.
All times listed are Pacific Standard Time (PST) (GMT -8).
Late-Breaking Science Main Event Sessions
Opening Main Event
| Time | Activity |
|---|---|
| 11:35 a.m. | MIND - LB1. Procedural, safety, and functional outcomes following minimally invasive surgery for deep and lobar intracranial hemorrhages: MIND study results
Adam S Arthur, Semmes-Murphey Clinic, Memphis, TN |
| 11:47 a.m. | TRACE - LB2. TransRadial versus transfemoral Arterial access for CErebral angiography Wei Ni, Huashan Hospital, Fudan University, Shanghai, China |
| 11:59 a.m. | DISTAL - LB3. Endovascular therapy plus best medical treatment versus best medical treatment alone for medium distal vessel occlusion stroke Marios Psychogios, University Hospital Basel, Basel, Switzerland |
| 12:11 p.m. | ESCAPE-MeVO - LB4. Endovascular treatment to improve outcomes for medium vessel occlusions: The ESCAPE-MeVO trial Mayank Goyal, University of Calgary, Calgary, AB, Canada |
| 12:31 p.m. | DISCOUNT - LB47. Mechanical Thrombectomy in Acute Ischemic Stroke Related to a Distal Arterial Occlusion: Interim Analysis of the DISCOUNT Randomized Controlled Trial Frederic Clarencon, Pitié-Salpêtrière Hospital, Paris, France |
Thursday Main Event
| Time | Activity |
|---|---|
| 11:30 a.m. | TRANSPORT2 - LB16. TRANScranial direct current stimulation for POst-stroke motor Recovery - a phase II sTudy (TRANSPORT2) - Main Results Wayne Feng, Duke University School of Medicine, Chapel Hill, NC |
| 11:42 a.m. | LB17. Intensive Blood Pressure Lowering After Thrombectomy in Ischemic Stroke Patients-A Randomized Clinical Trial Xuening Zhang, West China Hospital, Chendu, China |
| 11:54 a.m. | C3FIT - LB18. Coordinated, Collaborative, Comprehensive, Family-based, Integrated, Technology-enabled Post-Stroke Care Leann Long, Wake Forest School of Medicine, Winston Salem, NC |
| 12:06 a.m. | ICH-ADAPT - LB19. The Intracerebral Hemorrhage acutely decreasing arterial pressure trial II Final Results Ken Butcher, University of New South Wales, Randwick, NSW, Australia |
| 12:18 a.m. | LB20. Atorvastatin Treatment and Rebleeding in Cerebral Cavernous Malformations: A Randomized, Placebo-Controlled, Double-Blinded Clinical Trial Issam A Awad, Univ Chicago Medica Center, Chicago, IL |
Closing Main Event
| Time | Activity |
|---|---|
| 11:15 a.m. | PRESTIGE-AF - LB37. Effects of Direct Oral Anticoagulants Versus No Anticoagulation In the Prevention of Stroke in Intracerebral Haemorrhage Survivors with Atrial Fibrillation (PRESTIGE-AF) Trial Roland Veltkamp, Imperial College London, London, United Kingdom |
| 11:27 a.m. | ANGEL-TNK - LB38. Intra-arterial Tenecteplase thrombolysis for acute LVO after successful mechanical thrombectomy recanalization (ANGEL-TNK) — A Multicenter, Prospective, Randomized, Open-label, Blinded End-point Trial Miao Zhongrong, Beijing Tiantan Hospital, Beijing, China |
| 11:39 a.m. | DATE - LB39. The Optimal Dosage of ADjunctive Intra-Arterial Tenecteplase following Successful Endovascular Thrombectomy in Patients with Large Vessel Occlusion Acute Ischemic Stroke (DATE) Trail Xianhua Hou, The First Affiliated Hospital, Army Medical University, Chongqing, China |
| 11:51 a.m. | ETERNAL-LVO - LB40. Extending the Time Window for Tenecteplase by Effective Reperfusion of Penumbral Tissue in Patients with Large Vessel Occlusion (ETERNAL-LVO): a multicentre, prospective, open-label, blinded endpoint, controlled, phase III, superiority trial Vignan Yogendrakumar, The Ottawa Hospital, Ottawa, ON, Canada |
| 12:03 p.m. | HOPE - LB41. Treatment with intravenous alteplase in ischemic stroke patients with onset time between 4.5 and 24 hours Min Lou, The Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, China |
| 12:15 p.m. | PEARL LB42. Intra-arterial Alteplase for Acute Ischemic Stroke After Mechanical Thrombectomy (PEARL): A Multicenter Randomized Trial Yamei Tang, Sun Yat-sen Memorial Hospital, Guangzhou, China |
| 12:27 p.m. | ATIS-NVAF - LB43. A randomized controlled trial of antithrombotic therapy in ischemic stroke patients with non-valvular atrial fibrillation and atherosclerosis: The ATIS-NVAF trial Shuhei Okazaki, NHO Osaka National Hospital, Osaka, Japan |
| 12:39 p.m. | LAMP - LB44. Liraglutide in Acute Minor Ischemic Stroke or High-risk Transient Ischemic Attack Patients with Type 2 Diabetes Mellitus (LAMP): A Randomized Clinical Trial Huili Zhu, The First Affiliated Hospital of Jinan University, Guangzhou, China |
| 12:51 p.m. | BEST - LB45. BXOS110 for Acute Ischemic Stroke Treatment (BEST): A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Phase 2 Trial Yarong Ding, Beijing Tiantan Hospital, Beijing, China |
Late Breaking Science Concurrent Oral Abstract Sessions
Late-Breaking Science Oral Abstracts I
2:00 p.m. to 3:00 p.m.
| Time | Activity |
|---|---|
| 2:00 p.m. | LB5. Volume of brain saved in patients with a medium distal vessel occlusion stroke treated with endovascular therapy plus best medical treatment versus best medical treatment alone: A sub-analysis of the DISTAL Trial Aikaterini Anastasiou, University Hospital Basel, Basel, Switzerland |
| 2:12 p.m. | SYCAMORE - LB6. The SYCAMORE Study Results: First Randomized, Placebo-Controlled Phase 2 Trial in Symptomatic Cerebral Cavernous Malformation (CCM) Evaluating REC-994 Jan-Karl Burkhardt, Penn Medicine, Philadelphia, PA |
| 2:24 p.m. | EMPHASIS - LB7. Efficacy and Safety of Minocycline in Patients with Acute Ischemic Stroke (EMPHASIS): a randomized control trial Yilong Wang, Beijing Tiantan Hospital, Beijing, China |
| 2:36 p.m. | LB8. Targeting Cerebral Amyloid Angiopathy at its Source: An Amyloid Beta Precursor Protein-Targeted siRNA Reduced Vascular Amyloid Beta and Hemorrhage in Rodent Models Kirk Brown, Alnylam Pharmaceuticals, Inc., Massachusetts, Cambridge |
Late Breaking Science Oral Abstracts II
9:15 a.m. to 10:45 a.m.
| Time | Activity |
|---|---|
| 9:15 a.m. | LB9. Clinical Benefit of Nerinetide at One Year in Early Window Participants Enrolled in ESCAPE-NEXT Corey Adams, NoNO Inc., Toronto, ON, Canada |
| 9:27 a.m. | LB10. Impact of Socioeconomic Status on Quality and Clinical Outcomes in Acute Ischemic Stroke Patients: Findings from Get With The Guidelines®-Stroke Kathie Thomas, American Heart Association, Grand Rapids, MI |
| 9:39 a.m. | LB11. More Severe Disruption of the Blood-Brain Barrier Predicts Greater Progression of Cerebral Small Vessel Disease Richard Leigh, Johns Hopkins University, Towson, MD |
| 9:51 p.m. | LB12. Efficacy of otaplimastat in cute stroke patients requiring reperfusion therapy standard of care: a pooled analysis of two double-blind, randomized, placebo-controlled studies Jong S Kim, Gangneung Asan Hospital, Seoul, Korea (the Republic of) |
| 10:03 a.m. | LB13. Stability of flow diverter braids in INSPIRE-A: biomechanical predictors and clinical relevance Jens Fiehler, University Medical Center Hamburg, Hamburg, Germany |
| 10:15 a.m. | LB14. The Efficacy of Papaverine to Prevent Radial Artery Spasm During Transradial Cerebral Angiography (PASS): A Multicenter Randomized Trial Yamei Tang, Sun Yat-sen Memorial Hospital, Guangzhou, China |
| 10:27 a.m. | LB15. Results Of The First Randomized Controlled Trial Of Intravenous Alteplase Initiated Within 4.5 Hours Of Central Retinal Artery Occlusion (CRAO): The THEIA Study Benoit Guillon, University Hospital, Nantes, France |
| 10:39 a.m. | Discussion |
Late Breaking Science Oral Abstracts III
2:00 p.m. to 3:00 p.m.
| Time | Activity |
|---|---|
| 2:00 p.m. | LB21. Efficacy and Safety of Intra-Arterial Thrombolysis Following Endovascular Reperfusion for Large-Vessel Occlusion Acute Ischemic Stroke: An Individual Patient Data Meta-Analysis of POST-UK and POST-TNK Randomized Trial Wenjie Zi, Xinqiao Hospital, Choqi, China |
| 2:12 p.m. | LB22. Glucagon-Like Peptide-1 Receptor Agonist in Large Vessel Occlusion Stroke Treated by Reperfusion Therapy – a randomized trial Bonaventure Yiu Ming Ip, The Chinese University of Hong Kong, Shatin, China |
| 2:24 p.m. | LB23. Transauricular vagus nerve stimulation decreases inflammatory biomarkers and affects NIHSS in acute ischemic stroke patients: Results from the NUVISTA trial Osvaldo Laurido-Soto, Washington University in St. Louis, Saint Louis, MO |
| 2:36 p.m. | LB24. Emergency Stroke Unit for Acute Cerebrovascular Events - A multicenter, alternating-week, randomized, controlled trial Yongjun Wang, Beijing Tiantan Hospital, CMU, Beijing, China |
| 2:48 p.m. | Discussion |
Late Breaking Science Oral Abstracts IV
2:00 p.m. to 3:00 p.m.
| Time | Activity |
|---|---|
| 2:00 p.m. | LB25. Updated results from the multicentric, randomized study of sovateltide (Tycamzzi™) in acute cerebral ischemic stroke patients Anil Gulati, Pharmazz, Inc., Willowbrook, IL |
| 2:12 p.m. | LB26. Comparative Effectiveness of Direct oral Anticoagulants and warfarin in Reduced ejection fraction after stroke (CEDAR) Rami Morsi, University of Chicago, Chicago, IL |
| 2:24 p.m. | LB27. Dementia-Free Survival Differs by Midlife Blood Pressure and Genetic Risk Groups: The Atherosclerosis Risk in Communities (ARIC) Study Valerie Morrill, NIH, Bethesda, MD |
| 2:36 p.m. | LB28. SPRIN2G-D nomogram: A Reliable Tool to Predict the 90-day Unfavorable Prognosis in Minor Ischemic Stroke Patients Receiving Intravenous Thrombolysis Huijuan Jin, Wuhan Union Hospital, Wuhan, China |
| 2:48 p.m. | Discussion |
Late Breaking Science Oral Abstracts V
3:30 p.m. to 4:30 p.m.
| Time | Activity |
|---|---|
| 3:30 p.m. | LB29. Rapid administration of enteral nutrition reduces complications and is non-inferior to conventional administration in acute stroke patients: The Rapid EN Randomized Clinical Trial Kentaro Suzuki, Nippon Medical School, Tokyo, Japan |
| 3:42 p.m. | LB30. Cerebral Blood Flow Response to Intrathecal Nicardipine is Associated with Delayed Cerebral Ischemia after Subarachnoid Hemorrhage Ofer Sadan, Atlanta, GA |
| 3:54 p.m. | LB31. Infarct growth rate and tenecteplase benefit in ischemic stroke at 4.5 to 24 hours without thrombectomy: A secondary analysis of the TRACE-3 trial Yunyun Xiong, Beijing Tiantan Hospital, Beijing, China |
| 4:06 p.m. | LB32 Spatio-temporal Progression of Focal Ischemic White Matter Injury Hung Nguyen, Oregon Health Science University, Portland, OR |
| 4:18 p.m. | Discussion |
Late Breaking Science Oral Abstracts VI
4:45 p.m. to 5:45 p.m.
| Time | Activity |
|---|---|
| 4:45 p.m. | LB33. Increase in Acute Ambient Particulate Matter Before Stroke is Associated with Deterioration in Early Stroke Outcomes Kristina Shkirkova, Keck School of Medicine of USC, Los Angeles, CA |
| 4:57 p.m. | LB34. Identification of potential neuroprotective drug targets for ischemic stroke from genetic insights: a Mendelian randomization study Xinyan Wang, Beijing Tiantan Hospital, CCMU, Beijing, China |
| 5:09 p.m. | LB35. The EMBOLISE Observation Study: Embolization of the Middle Meningeal Artery with ONYXTM Liquid Embolic System In the Treatment of Subacute and Chronic Subdural HEmatoma Jason Michael Davies, University at Buffalo, Buffalo, NY |
| 5:21 p.m. | LB36. Central nervous system fibroblasts mediate extracellular matrix remodeling in Cerebral Amyloid Angiopathy Kiersten Scott, UTHealth, Houston, TX |
| 5:33 p.m. | Discussion |
Helpful Hints
- Trial results are prohibited from release until date and time of AHA designated embargo time. For Main Event and Concurrent Oral Abstract Late-Breaking Science, the embargo time is the date and time of presentation at the International Stroke Conference 2025. Clinical trial sponsors must comply with embargo guidelines and policy established by the American Heart Association.
- You are prohibited from sharing written embargoed information with anyone outside of the AHA with the exception of journal manuscript submission. Important Note: Industry announcements required by the SEC (Security Exchange Commission) must be approved by AHA prior to release and any level of information released without approval will be considered an embargo break.